Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics
Details : Under the licensing agreement, Revio will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2025
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 24, 2021
RT001 in Amyotrophic Lateral Sclerosis
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 21, 2021
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RT001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 25, 2019
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RT001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Details : RT001 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neuroaxonal Dystrophies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 27, 2018
Lead Product(s) : RT001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
Details : RT001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 15, 2015
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RT001
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lateral Canthal Lines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 17, 2010
Lead Product(s) : RT001
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
